ANI Pharmaceuticals (NASDAQ:ANIP) Raised to Hold at StockNews.com

StockNews.com upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday.

Several other equities research analysts have also issued reports on ANIP. Guggenheim raised their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Finally, Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a report on Friday. They set a "buy" rating and a $80.00 target price on the stock. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $79.75.

Remove Ads

ANI Pharmaceuticals Stock Down 0.2 %

Shares of ANIP traded down $0.13 on Friday, reaching $64.22. The company's stock had a trading volume of 233,027 shares, compared to its average volume of 238,092. The firm has a fifty day moving average of $58.79 and a 200-day moving average of $58.07. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The stock has a market capitalization of $1.40 billion, a PE ratio of -116.76 and a beta of 0.63.

Insider Buying and Selling

In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now owns 68,624 shares of the company's stock, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,200 shares of company stock worth $191,776. Corporate insiders own 12.70% of the company's stock.

Institutional Trading of ANI Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after buying an additional 340,854 shares during the period. Global Alpha Capital Management Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after purchasing an additional 9,500 shares during the period. Thompson Siegel & Walmsley LLC boosted its holdings in shares of ANI Pharmaceuticals by 17.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock worth $13,731,000 after purchasing an additional 34,416 shares during the period. Thrivent Financial for Lutherans boosted its holdings in shares of ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after purchasing an additional 299 shares during the period. Finally, Mizuho Markets Americas LLC purchased a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $11,670,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.